Gupta Ekta, Mishra Rupesh Kumar, Kumar Niraj Ravi Ranjan
Dr. B. Lal Institute of Biotechnology Jaipur India.
Amity University Rajasthan Jaipur India.
JMIR Bioinform Biotechnol. 2022 Apr 26;3(1):e32401. doi: 10.2196/32401. eCollection 2022 Jan-Dec.
The recent emergence of COVID-19 has caused an immense global public health crisis. The etiological agent of COVID-19 is the novel coronavirus SARS-CoV-2. More research in the field of developing effective vaccines against this emergent viral disease is indeed a need of the hour.
The aim of this study was to identify effective vaccine candidates that can offer a new milestone in the battle against COVID-19.
We used a reverse vaccinology approach to explore the SARS-CoV-2 genome among strains prominent in India. Epitopes were predicted and then molecular docking and simulation were used to verify the molecular interaction of the candidate antigenic peptide with corresponding amino acid residues of the host protein.
A promising antigenic peptide, GVYFASTEK, from the surface glycoprotein of SARS-CoV-2 (protein accession number QIA98583.1) was predicted to interact with the human major histocompatibility complex (MHC) class I human leukocyte antigen (HLA)-A*11-01 allele, showing up to 90% conservancy and a high antigenicity value. After vigorous analysis, this peptide was predicted to be a suitable epitope capable of inducing a strong cell-mediated immune response against SARS-CoV-2.
These results could facilitate selecting SARS-CoV-2 epitopes for vaccine production pipelines in the immediate future. This novel research will certainly pave the way for a fast, reliable, and effective platform to provide a timely countermeasure against this dangerous virus responsible for the COVID-19 pandemic.
新型冠状病毒肺炎（COVID-19）的近期出现引发了巨大的全球公共卫生危机。COVID-19的病原体是新型冠状病毒SARS-CoV-2。当下迫切需要在开发针对这种新发病毒性疾病的有效疫苗领域开展更多研究。
本研究旨在识别有效的候选疫苗，为抗击COVID-19的斗争提供新的里程碑。
我们采用反向疫苗学方法，在印度流行的毒株中探索SARS-CoV-2基因组。预测表位，然后使用分子对接和模拟来验证候选抗原肽与宿主蛋白相应氨基酸残基的分子相互作用。
预测来自SARS-CoV-2表面糖蛋白（蛋白质登录号QIA98583.1）的一种有前景的抗原肽GVYFASTEK与人类主要组织相容性复合体（MHC）I类人类白细胞抗原（HLA）-A*11-01等位基因相互作用，保守性高达90%，且抗原性值高。经过严格分析后，该肽被预测为能够诱导针对SARS-CoV-2的强烈细胞介导免疫反应的合适表位。
这些结果有助于在不久的将来为疫苗生产流程选择SARS-CoV-2表位。这项新研究必将为一个快速、可靠且有效的平台铺平道路，以便及时应对导致COVID-19大流行的这种危险病毒。
